Harvard Bioscience, Inc.
HBIO
$6.04
$0.030.50%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -6.42% | -8.06% | -10.60% | -12.24% | -14.41% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -6.42% | -8.06% | -10.60% | -12.24% | -14.41% |
| Cost of Revenue | -9.23% | -6.83% | -6.83% | -8.50% | -10.90% |
| Gross Profit | -4.31% | -8.94% | -13.25% | -14.87% | -16.87% |
| SG&A Expenses | -15.23% | -18.28% | -15.60% | -13.53% | -9.44% |
| Depreciation & Amortization | -27.45% | -23.37% | -17.66% | -9.22% | -7.09% |
| Other Operating Expenses | -- | -79.12% | -79.12% | -79.12% | -97.52% |
| Total Operating Expenses | -12.94% | -14.20% | -13.26% | -12.27% | -11.44% |
| Operating Income | 144.39% | 125.58% | 67.70% | 13.07% | -195.69% |
| Income Before Tax | 82.93% | -391.95% | -301.20% | -503.98% | -602.98% |
| Income Tax Expenses | -251.32% | -192.70% | -72.48% | -63.41% | -84.30% |
| Earnings from Continuing Operations | 83.15% | -357.07% | -278.03% | -437.61% | -564.88% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 83.15% | -357.07% | -278.03% | -437.61% | -564.88% |
| EBIT | 144.39% | 125.58% | 67.70% | 13.07% | -195.69% |
| EBITDA | 206.33% | 269.32% | 99.83% | 7.37% | -54.79% |
| EPS Basic | 83.35% | -350.45% | -271.87% | -427.30% | -549.89% |
| Normalized Basic EPS | -2.37% | 5.78% | 51.25% | -7.10% | -21.94% |
| EPS Diluted | 83.14% | -348.55% | -270.66% | -421.53% | -541.19% |
| Normalized Diluted EPS | -2.19% | 5.94% | 51.10% | -7.30% | -22.15% |
| Average Basic Shares Outstanding | 1.91% | 1.95% | 1.97% | 1.97% | 2.16% |
| Average Diluted Shares Outstanding | 1.44% | 1.49% | 2.43% | 2.43% | 2.63% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |